News

They can weather many storms.

Moby summary of Codexis, Inc.'s Q1 2026 earnings call

An $83,400 annual paycheck sits comfortably above the U.S. median household income of roughly $80,610. Replacing that income with a portfolio, no employer required, is the question this article answers. The basic formula is income target divided by yield equals capital required. The more important issue is what changes across three yield tiers, and why ... A $1.5 Million Portfolio That Quietly Pays You $83,400 a Year, No Job Required

Over the last 7 days, the United States market has risen 3.2%, contributing to a 31% increase over the past year, with earnings expected to grow by 16% per annum in the coming years. In this thriving environment, identifying stocks that are trading below their estimated intrinsic value can be an effective strategy for investors looking to capitalize on potential growth opportunities.

Elizabeth Schwartz will head up government relations at the for-profit hospital trade association as health systems brace for federal funding cuts.

Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million

Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

Mounjaro generated $8.66 billion in sales in the first quarter.

Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.

Merck Animal Health selects Salesforce's Agentforce Life Sciences to support unified omnichannel engagement for veterinarians and animal health providers. New integrations from eGain and Mili extend Salesforce's AI capabilities into Service Cloud and private client workflows. These customer wins and ecosystem additions highlight further adoption of Salesforce's AI platform beyond prior product announcements. For investors watching Salesforce (NYSE:CRM), the focus has shifted from product...

EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.

Wondering whether Merck’s current share price reflects its real value, or if the stock might be pricing in more than it should. Merck closed at US$113.15, with returns of 2.8% over 7 days, a 6.4% decline over 30 days, 6.3% year to date and 48.4% over the last year. Recent headlines around Merck have kept investors focused on how the company is being priced, with attention on its long term prospects and capital allocation decisions. This context helps explain why the stock’s recent moves have...

AMD upgraded, Reddit downgraded: Wall Street's top analyst calls

The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of